Originally posted by Hokucat
View Post
Yes, I am still in the fitting process after all these months - as said in a post I just wrote, it looks like the trial period restarts with every new manufacturer.
Now I am disappointed about the unavailability of lacosamide, after the initial excitement when I was convinced it would help with the most disbilitating symptom I have right now (photosensitivity). Am waiting to hear back from the compounding pharmacy who said they wrote a few manufacturers, and am prepared I would hear a negative.
On the other hand, I see there are other 2 medications that are used a related study, with favourable results, although I do not see references of them being prescribed for this purpose. I brought this up when I saw the associate optometrist today, but am not positive I would be able to get it:
**https://www.aao.org/eyenet/article/a...eal-neuropathy
**http://bostoneyepain.org/patients-as-teachers/
http://australiandryeye.webs.com/app...ve-as-a-razor-
... right scleral lens was medicated with sterile, non-preserved bupivacaine 0.004%. Moments after its open label insertion she reported total resolution of pain and photophobia in that eye
...Subsequent daily treatment of both corneas with anarbitrarily chosen mixture of ropivacaine 0.005% andlacosamide 0.05% in the scleral lens chambers strikingly suppressed symptoms of photosensitivity, DELP and hypersensitivity to fumes. This analgesic effect continued for 2 years at which time the drugs in the scleral lenses were deliberately discontinued. Pain and photophobia returned to its previous levels within 2 weeks. Reinstitution of the treatment again suppressed the neuropathic symptoms.
...Subsequent daily treatment of both corneas with anarbitrarily chosen mixture of ropivacaine 0.005% andlacosamide 0.05% in the scleral lens chambers strikingly suppressed symptoms of photosensitivity, DELP and hypersensitivity to fumes. This analgesic effect continued for 2 years at which time the drugs in the scleral lenses were deliberately discontinued. Pain and photophobia returned to its previous levels within 2 weeks. Reinstitution of the treatment again suppressed the neuropathic symptoms.

Leave a comment: